Combinatorial strategies for the induction of immunogenic cell death by Bezu, Lucillia et al.
REVIEW
published: 24 April 2015
doi: 10.3389/fimmu.2015.00187
Edited by:
Patrizia Agostinis,
University of Leuven, Belgium
Reviewed by:
Stephan Gasser,
National University of Singapore,
Singapore
Luis De La Cruz-Merino,
Hospital Universitario Virgen
Macarena, Spain
*Correspondence:
Oliver Kepp and Guido Kroemer,
INSERM U1138, Centre des
Recherche des Cordeliers, Equipe 11,
15 rue de l’Ecole de Médecine,
Paris 75005, France
oliver.kepp@gustaveroussy.fr;
kroemer@orange.fr
†Equally contributed to this work.
‡Shared senior co-authorship.
Specialty section:
This article was submitted to Tumor
Immunity, a section of the journal
Frontiers in Immunology
Received: 12 March 2015
Accepted: 06 April 2015
Published: 24 April 2015
Citation:
Bezu L, Gomes-de-Silva LC, Dewitte
H, Breckpot K, Fucikova J, Spisek R,
Galluzzi L, Kepp O and Kroemer G
(2015) Combinatorial strategies for the
induction of immunogenic cell death.
Front. Immunol. 6:187.
doi: 10.3389/fimmu.2015.00187
Combinatorial strategies for the
induction of immunogenic cell death
Lucillia Bezu 1,2,3,4†, Ligia C. Gomes-de-Silva 1,2,3,5†, Heleen Dewitte 6,7, Karine Breckpot 7,
Jitka Fucikova 8,9, Radek Spisek 8,9, Lorenzo Galluzzi 1,2,10,11,12‡, Oliver Kepp 1,2,3‡* and
Guido Kroemer 1,2,3,9,11,12,13‡*
1 Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France, 2 U1138,
INSERM, Paris, France, 3 Metabolomics and Cell Biology Platforms, Gustave Roussy Campus Cancer, Villejuif,
France, 4 Faculté de Medecine, Université Paris-Sud, Le Kremlin-Bicêtre, France, 5 Department of Chemistry, University of
Coimbra, Coimbra, Portugal, 6 Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharmacy, Ghent
University, Ghent, Belgium, 7 Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Jette, Belgium, 8 Sotio
a.c., Prague, Czech Republic, 9 Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles
University, Prague, Czech Republic, 10 Gustave Roussy Campus Cancer, Villejuif, France, 11 Université Paris Descartes, Paris,
France, 12 Université Pierre et Marie Curie, Paris, France, 13 Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP,
Paris, France
The term “immunogenic cell death” (ICD) is commonly employed to indicate a peculiar
instance of regulated cell death (RCD) that engages the adaptive arm of the immune
system. The inoculation of cancer cells undergoing ICD into immunocompetent animals
elicits a specific immune response associated with the establishment of immunological
memory. Only a few agents are intrinsically endowed with the ability to trigger ICD.
These include a few chemotherapeutics that are routinely employed in the clinic, like
doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well as some agents
that have not yet been approved for use in humans. Accumulating clinical data indicate
that the activation of adaptive immune responses against dying cancer cells is associated
with improved disease outcome in patients affected by various neoplasms. Thus, novel
therapeutic regimens that trigger ICD are urgently awaited. Here, we discuss current
combinatorial approaches to convert otherwise non-immunogenic instances of RCD into
bona fide ICD.
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Introduction
The expression “immunogenic cell death” (ICD) generally refers to a functionally peculiar case of
regulated cell death (RCD) that – in immunocompetent hosts – is capable of activating an adaptive
immune response against dead cell-associated antigens (1–5). Of note, ICD generally (but not
obligatorily) manifests with apoptotic morphological features, and at least some of its manifestations
depend on components of the apoptotic apparatus (6–8). Irrespective of these morphological and
biochemical considerations, immunocompetent mice injected s.c. with cancer cells succumbing to
Abbreviations: APC, antigen-presenting cell; CALR, calreticulin; CTLA4, cytotoxic T lymphocyte-associated protein 4;
CXCL10, chemokine (C–X–C motif) ligand 10; DAMP, damage-associated molecular pattern; EIF2A, eukaryotic translation
initiation factor 2A, 65 kDa; ER, endoplasmic reticulum; HMGB1, high-mobility group box 1; ICD, immunogenic cell death;
IFN, interferon; IFNAR, interferon (alpha, beta, and omega) receptor; mAb, monoclonal antibody; P2RX7, purinergic receptor
P2X, ligand gated ion channel, 7; P2RY2, purinergic receptor P2Y, G-protein coupled, 2; RCD, regulated cell death; siRNA,
small-interfering RNA; TLR, toll-like receptor.
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bona fide ICD (in the absence of any adjuvant) develop a cellular
immune response associated with the establishment of immuno-
logical memory that protects them from a subsequent challenge
with living cells of the same type (1–3). Importantly, vaccination
experiments of this type, involving murine cells and syngeneic
mice, remain the gold-standardmethod to identify bona fide ICD,
though several tests have been developed to detect some of its
cellular manifestations (see below) (2, 3, 9, 10).
Only a few lethal stimuli are intrinsically endowed with the
ability to trigger ICD (9, 11–14). These include some chemother-
apeutic agents that are employed in the clinic, including (1) vari-
ous anthracyclines (i.e., doxorubicin, epirubicin, and idarubicin),
which are commonly used against a wide panel of malignant
conditions (15–17); (2) mitoxantrone, an anthracenedione gen-
erally used for the treatment of acute myeloid leukemia, breast
carcinoma, non-Hodgkin’s lymphoma, and prostate carcinoma
(15, 16); (3) oxaliplatin, a platinum derivative approved for use in
combination with 5-fluorouracil to treat advanced colorectal car-
cinoma (18, 19); (4) cyclophosphamide, an alkylating agent that is
employed against various neoplastic and autoimmune conditions
(20–23); and (5) bortezomib, a proteasomal inhibitor approved for
the therapy of multiple myeloma and mantle cell lymphoma (24–
26). Specific forms of irradiation as well as photodynamic therapy,
both of which are habitually employed for the treatment of various
neoplasms, have also been shown to trigger bona fide ICD (27–34).
Finally, a bunch of hitherto experimental agents is intrinsically
endowed with the capacity to initiate ICD, including (but not lim-
ited to) some oncolytic viruses (35–39), themicrotubular inhibitor
patupilone (40–42), and elevated hydrostatic pressures (43).
According to accepted models, ICD relies on the establishment
of adaptive stress responses that promote the spatiotemporally
coordinated emission of endogenous danger signals from dying
cells (44, 45). The endogenous molecules that dispatch danger
signals in response to stress are cumulatively known as “damage-
associated molecular patterns” (DAMPs) and operate upon bind-
ing to receptors expressed by bystander cells, including cellular
components of both the innate and adaptive immune system (2,
46–49). As it stands, four DAMPs have been shown to be required
for RCD as induced by anthracyclines to be perceived as immuno-
genic, namely, (1) the exposure of the endoplasmic reticulum
(ER) chaperone calreticulin (CALR) on the outer surface of the
plasma membrane (16); (2) the secretion of ATP (50); (3) the
production of type I interferon (IFN) (51); and (4) the release of
the non-histone chromatin-binding protein high-mobility group
box 1 (HMGB1) into the extracellular space (52). This said, it
cannot be formally excluded that other hitherto undiscovered
DAMPs are required for anthracycline-elicited RCD to promote
an adaptive immune response. Along similar lines, not all these
DAMPsmay be required for RCD as induced by agents other than
anthracyclines to be perceived as immunogenic (53–55).
In this context, i.e., anthracycline-induced ICD, CALR expo-
sure obligatorily relies on the establishment of a pre-mortem ER
stress response centered around the phosphorylation of eukary-
otic translation initiation factor 2A, 65 kDa (EIF2A) (7, 56), ATP
secretion requires the induction of autophagy (57), and type
I IFN production stems from toll-like receptor 3 (TLR3) sig-
naling (51). The molecular mechanisms underlying the ability
of anthracyclines and other ICD inducers to promote HMGB1
release remain obscure (2, 3). Cumulatively, these DAMPs recruit
antigen-presenting cells (APCs) to sites of active ICD and stim-
ulate the uptake, processing, and presentation of dead cell-
associated antigens, eventually resulting in the priming of an
adaptive immune response (2, 3). In particular, CALR promotes
antigen uptake by APCs by binding to low density lipoprotein
receptor-related protein 1 (LRP1, best known as CD91) (58);
ATP stimulates the recruitment of APCs and their activation
upon binding to purinergic receptor P2Y, G-protein coupled, 2
(P2RY2) and purinergic receptor P2X, ligand-gated ion channel,
7 (P2RX7), respectively (50, 59, 60); type I IFNs exert immunos-
timulatory effects via IFN (alpha, beta, and omega) receptors
(IFNARs) (51); andHMGB1 does so through TLR4 and advanced
glycosylation end product-specific receptor (AGER, best known
as RAGE) (52, 61).
A detailed discussion of themolecular and cellularmechanisms
involved in the detection of ICD-associated DAMPs goes beyond
the scope of this review and can be found in Ref. (2, 3). How-
ever, it is important to note that the failure of cancer cells to
emit one (or more) of these DAMPs completely compromises the
immunogenicity of RCD (2, 3). Thus, at odds with their wild-
type counterparts, Calr /  murine CT26 colorectal cells exposed
to anthracyclines are unable to vaccinate mice against a subse-
quent inoculation with malignant cells of the same type (16).
The same holds true in several other situations in which adaptive
responses cannot proceed normally, including the genetic inhi-
bition of autophagy (e.g., upon the expression of short-hairpin
RNAs targeting the essential autophagy proteins Atg5 or Atg7)
or the unfolded protein response (e.g., upon the expression of a
non-phosphorylatable variant of EIF2A) (7, 57, 62, 63).
Accumulating clinical evidence indicates that the
(re-)activation of a proficient immune response against malignant
cells is associated with improved disease outcome in patients
affected by a wide panel of neoplasms (64–68), in particular
when malignant lesions are highly infiltrated by immune effector
cells prior to therapy (69). Considerable efforts are therefore
being devoted to the development of clinically implementable
strategies that (re-)instate anticancer immunosurveillance (70,
71). So far, the most successful of these approaches involves
the administration of monoclonal antibodies (mAbs) that
block immunosuppressive receptors expressed by activated
T cells, such as cytotoxic T lymphocyte-associated protein 4
(CTLA4) and programed cell death 1 (PDCD1, best known as
PD-1) (72, 73). Three distinct checkpoint blockers of this type,
namely, the CTLA4-targeting mAb ipilimumab and the PD-1-
targeting mAbs nivolumab and pembrolizumab, are approved
by the US Food and Drug Administration and other regulatory
agencies worldwide for use as standalone immunotherapeutic
interventions in melanoma patients (74–77). In addition, the
administration of checkpoint blockers has been shown to
improve the clinical profile of various chemotherapeutic and
immunotherapeutic agents (78). Along similar lines, various
combinatorial immuno(chemo)therapeutic regimens are being
investigated in clinical trials for their ability to mediate superior
antineoplastic effects as compared to monotherapies based on
their constituents (79, 80). In this framework, various attempts are
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beingmade to render immunogenic otherwise non-immunogenic
instances of therapy-induced RCD, thereby converting them into
bona fide ICD (79, 81–84). This can be due to molecular defects
that prevent cancer cells from emitting DAMPs appropriately,
as mentioned above, as well as to the intrinsic features of the
therapeutic agent under consideration (Table 1). For instance,
at odds with its derivative oxaliplatin, cisplatin is intrinsically
unable to trigger ICD since it does not stimulate the exposure of
CALR on the outer surface of the plasma membrane (18, 19, 85).
Here, we discuss strategies to convert non-immunogenic
instances of RCD into bona fide ICD. In particular, we will review
approaches for (1) correcting the incapacity of some therapeutic
agents to kill cancer cells while provoking the emission of one
or more DAMP(s); or (2) complementing the missing DAMP(s)
with exogenous interventions. On the contrary, we will not dwell
on strategies that boost the immunogenicity of RCD by operating
downstream of DAMP-sensing receptors.
Combinatorial Strategies to Restore CALR
Exposure
Some anticancer therapeutics efficiently kill cancer cells (hence
promoting the release of HMGB1) and stimulate the secretion of
both ATP and type I IFNs, but selectively fail to promote CALR
exposure. Most often, such a defect originates from the inability
of these agents to trigger an ER stress response resulting in EIF2A
phosphorylation (56, 114), and hence can be corrected by the co-
administration of an ER stressors. As mentioned above, cisplatin
is one of the antineoplastic agents that fail to trigger bona fide
ICD as it does not drive a robust ER stress response (18, 19,
85). The ER-stressing agents that have been shown to correct this
defect, hence rendering cisplatin-induced RCD immunogenic,
include thapsigargin, an inhibitor of various members of the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) (19, 114);
tunicamycin, an inhibitor of N-glycosylation (19, 94, 114); pyri-
doxine, a cell-permeant precursor of bioactive vitamin B6 (90, 91,
115); and ZnCl2 (92). Similar results have been obtained by estab-
lishing an ER stress response through the enforced overexpression
of reticulon 1 (RTN1), an ER protein involved in vesicular traf-
ficking and secretion (116, 117). The latter approach is obviously
incompatible with clinical applications. Nonetheless, these data
reinforce the notion that the immunogenicity of cisplatin-induced
RCD can be restored by various interventions that induce an ER
stress (94).
Another strategy that successfully restores CALR exposure in
cells succumbing to chemicals that per se do not enable this
phenomenon consists in the co-administration of inhibitors of
the EIF2A phosphatase composed of protein phosphatase 1, reg-
ulatory subunit 15A (PPP1R15A, best known as GADD34), and
pyrophosphatase (inorganic) 1 (PPA1, best known as PP1), result-
ing in accruedEIF2Aphosphorylation even in the absence of overt
ER stress (16). Thus, whereas CT26 cells treated with etoposide
(a topoisomerase II inhibitor currently approved for the treat-
ment of various malignancies) (118, 119) do not expose CALR
as they die, and hence fail to vaccinate mice against a subsequent
challenge with neoplastic cells of the same type, they efficiently
do so in the presence of tautomycin, calyculin A, and salubrinal
(three distinct GADD34/PP1 inhibitors) (16). Similar results have
been obtained with the small-interfering RNA (siRNA)-mediated
downregulation of PP1 orGADD34 (16), as well as with short cell-
permeant peptides that disrupt the physical interaction between
these two proteins (102). Although siRNA- and peptide-based
strategies may not be easily implemented in clinical settings, these
results corroborate the specificity of tautomycin, calyculin A, and
salubrinal, and lend further support to the notion that interven-
tions that stimulate EIF2A phosphorylation efficiently promote
CALR exposure even in the absence of overt ER stress (120).
At least theoretically, the co-administration of ER stressors or
molecules that promote EIF2A phosphorylation can be harnessed
to reconstitute the immunogenicity of RCD induced by all anti-
cancer agents that per se do not stimulate CALR exposure on the
cell surface but provoke ATP secretion, type I IFN production,
and HMGB1 release. In addition, the inability of some anticancer
agents to cause the translocation of CALR to the outer leaflet of
the plasma membrane can be corrected, at least in some settings,
by the co-administration of exogenous, recombinant CALR (7,
16, 106). CALR is indeed relatively “sticky” and its absorption on
malignant cells succumbing to non-immunogenic RCD in vitro
has been shown to fully restore the ability of these cells to vaccinate
syngeneic mice against a subsequent neoplastic challenge (16).
To the best of our knowledge, however, whether the systemic
or intratumoral administration of recombinant CALR to tumor-
bearing mice treated with non-immunogenic therapeutics is able
to convert them into bona fide ICD inducers has not been tested
yet. As compared to administration of small molecules that estab-
lish an ER stress response or promote EIF2A phosphorylation, the
use of recombinant CALR appears advantageous in that (at least
theoretically) it would complement the lack of CALR exposure
in all scenarios, irrespective of the underlying molecular defects
(including the downregulation or loss of CALR itself). However,
such an approachmay not be implementable in the clinic, owing to
pharmacodynamic and pharmacokinetic issues (e.g., distribution
of the recombinant protein, serum half-life, etc: : :) as well as eco-
nomic considerations. Current efforts are therefore being focused
on the identification of novel (and the refinement of existing)
smallmolecule-based strategies to stimulate CALR exposure upon
the establishment of an ER stress or the induction of EIF2A
phosphorylation.
Combinatorial Strategies to Boost ATP
Secretion
In some settings, anticancer agents kill malignant cells in an
efficient fashion (which corresponds to a consistent release of
HMGB1), while stimulating the exposure of CALR and the pro-
duction of type I IFN, but this is not accompanied by the accumu-
lation of extracellular ATP (57, 121), a defect that can stem from
at least three different causes. First, some therapeutic agents are
unable to stimulate (or even inhibit) autophagic responses, which
are required for dying cells to secrete ATP in sufficient amount
for signaling via P2RY2 and P2RX7 receptors (57). Second, some
malignant cells bear genetic or epigenetic defects that affect the
molecular machinery for autophagy (122, 123). These cells are
intrinsically unable to preserve the intracellular ATP pool in the
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TABLE 1 | Immunogenicity of chemotherapy-induced regulated cell death (examples).
Drug CALR
exposure
ATP
secretion
Type I IFN
production
HMGB1
release
aBona fide
ICD inducer
Restoration
of ICD
Reference
5-Fluorouracil Debated No n.d. Yes n.d. RT (16)
(86)
(87)
Bleomycin Yes Yes Yes Yes Yes n.a. (88)
Bortezomib Yes n.d. Yes Yes Yes n.a. (24)
(25)
(26)
(89)
Camptothecin Debated No n.d. Yes No n.d. (16)
(87)
Carboplatin Partial Yes n.d. Partial No RT (16)
(86)
Cisplatin No Yes n.d. Yes No Pyridoxine (19)
Thapsigargin (90)
Tunicamycin (91)
ZnCl2 (92)
(93)
(94)
Cyclophosphamide Yes Yes Yes Yes Yes n.a. (20)
(21)
(95)
Digitoxin Yes Yes n.d. Partial No Cytotoxic agents (81)
Digoxin (83)
Docetaxel Yes No n.d. No No n.d. (96)
(97)
Doxorubicin Yes Yes Yes Yes Yes n.a. (15)
(16)
(17)
(51)
(98)
(99)
Epirubicin Yes Yes n.d. Yes Yes n.a. (16)
(17)
Etoposide No Yes n.d. Yes No Calyculin A (16)
Salubrinal (17)
Tautomycin (93)
PP1/GADD34-targeting peptides (100)
2-deoxyglucose (101)
(102)
Gemcitabine No Partial n.d. Yes No PX-478 (103)
Idarubicin Yes n.d. n.d. Yes Yes n.a. (17)
(16)
(104)
Irinotecan n.d. n.d. n.d. Yes n.d. n.d. (105)
Mafosfamide Yes n.d. n.d. Yes Yes n.d. (20)
(Continued)
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TABLE 1 | Continued
Drug CALR
exposure
ATP
secretion
Type I IFN
production
HMGB1
release
aBona fide
ICD inducer
Restoration
of ICD
Reference
Melphalan Debated n.d. n.d. Yes n.d. n.d. (106)
(107)
(108)
Mitomycin C Debated No n.d. Yes No n.d. (16)
(87)
Mitoxantrone Yes Yes Yes Yes Yes n.a. (7)
(16)
(17)
(51)
(57)
(93)
(109)
Oxaliplatin Yes Yes Yes n.d. Yes n.a. (7)
(18)
(52)
(57)
(93)
(110)
Patupilone Yesb n.d. Yes Yesb Yesb n.a. (41)
(42)
Temozolomide No Yes n.d. Yes n.d. Oncolytic virotherapy (111)
Cyclophosphamide (112)
Vemurafenib Yes n.d. n.d. Yes n.d. n.d. (103)
(113)
CALR, calreticulin; HMGB1, high-mobility group box 1; ICD, immunogenic cell death; IFN, interferon; n.a., not applicable; n.d., not determined; RT, radiation therapy.
aAs determined in gold-standard vaccination experiments.
bUnpublished observations from our group.
course of stress responses, resulting in limited ATP secretion
during death (124). Third, some neoplastic cells express high
levels of either ectonucleoside triphosphate diphosphohydrolase 1
(ENTPD1, best known as CD39) or 50-nucleotidase, ecto (NT5E,
best known as CD73), two membrane-bound nucleotidases that
degrade extracellular ATP (125).
So far, one general strategy has been shown to restore extra-
cellular ATP concentrations to levels that are compatible with
the efficient recruitment and activation of APCs, namely, the
pharmacological inhibition of CD39. Thus, CT26 cells lack-
ing essential components of the autophagic machinery, such
as Atg5, Atg7, or Beclin 1 (Becn1), secrete limited amounts of
ATP as they succumb to anthracyclines, and hence are incapable
of vaccinating syngeneic mice against a subsequent challenge
with malignant cells of the same type (57). Such a functional
defect can be corrected by the co-administration of ARL67156,
a broad spectrum inhibitor of extracellular nucleotidases (57).
Further confirming these findings, CT26 engineered to overex-
press CD39 and exposed to anthracyclines are unable to protect
syngeneic mice against a subsequent injection with neoplastic
cells of the same type (57, 125). This defect can be corrected by
the co-administration of ARL67156, along with the restoration of
RCD-associated ATP secretion (57, 125). Taken together, these
results indicate that inhibitors of extracellular nucleotidases may
constitute a convenient manner to boost the immunogenicity
of RCD instances that are normally not associated with ATP
secretion.
Importantly, the pharmacological activation of autophagy does
not suffice for cancer cells to become immunogenic (16, 57).
Nonetheless, combining anticancer agents that per se are unable
to trigger ATP secretion with molecules that upregulate the
autophagic flux, such as inhibitors of mechanistic target of
rapamycin (MTOR) complex I (MTORCI), may efficiently con-
vert non-immunogenic RCD instances into bona fide ICD. This
hypothesis awaits formal experimental confirmation. Indeed,
while other inducers of autophagy such as the glycolytic inhibitor
2-deoxyglucose (126) have been shown to reinstate the immuno-
genicity of etoposide-elicited RCD, such an effect was ascribed
to the restoration of CALR exposure (indeed, etoposide kills
malignant cells while promoting ATP secretion) (100). Finally,
it should be noted that the establishment of an ATP gradient
around dying cells may not constitute a general requirement for
the perception of RCD as immunogenic (127). Moreover, at least
in some settings, autophagy may actually inhibit ICD by limiting
the production of reactive oxygen species in the course of adaptive
stress responses, hence counteracting the establishment of ER
stress and consequentCALR exposure (54, 55). Thus, furtherwork
is required to precisely identify malignancies in which autophagy
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supports ICD. Only in these scenarios, the co-administration of
autophagy inducers may constitute a proper approach to reinstate
the immunogenicity of RCD.
Combinatorial Strategies to Promote Type I
IFN Production
Whereas the role of type I IFN in the regulation of innate and
adaptive immune responses is well known (128, 129), type I IFN
signaling in malignant cells has been identified as a requirement
for (anthracycline-induced) ICD only recently (51). Thus, cancer
cells respond to various anthracyclines by activating a TLR3-
elicited signal transduction cascade resulting in type I IFN release,
autocrine/paracrine type I IFN signaling, and chemokine (C–X–C
motif) ligand 10 (CXCL10) secretion, two phenomena that under-
lie their vaccinating potential. At odds with their wild-type coun-
terparts, Tlr3 /  and Ifnar1 /  murine cancer cells exposed to
anthracyclines fail to vaccinate syngeneic mice against a subse-
quent injection of living cells of the same type (51). It has already
been demonstrated that the inability of Tlr3 /  cells to undergo
ICD can be corrected by the co-administration of recombinant
type I IFNs or recombinant CXCL10. Similarly, Ifnar1 /  cells
succumbing to anthracyclines turn immunogenic in the presence
of recombinant CXCL10 (but not type I IFNs) (51).
Various synthetic TLR3 agonists are available and some of
them, including polyinosinic:polycytidylic acid (polyI:C) and its
clinical grade analog polyI:polyC12U (also known as rintatolimod
and Ampligen™), have been extensively tested as immunostim-
ulants in cancer patients (130, 131). It is therefore tempting to
speculate that the co-administration of TLR3 agonists may restore
the ability of anticancer agents that per se do not promote type
I IFN release to trigger bona fide ICD. This hypothesis awaits
urgent experimental confirmation. For the considerations pre-
sented above, small molecules that trigger TLR3 signaling would
indeed be more convenient as clinical tools to restore type I IFN
signaling than recombinant type I IFN or CXCL10 themselves.
Combinatorial Strategies to Substitute for
HMGB1 Release
HMGB1 release occurs upon (nuclear and) plasma membrane
permeabilization, i.e., it constitutes a post-mortem event (5, 132).
Thus, all antineoplastic agents that efficiently kill malignant cells
(as opposed tomolecules that exert cytostatic effects or induce cell
senescence) (133) promote HMGB1 release, perhaps with differ-
ent kinetics (5, 132). However, the expression levels of HMGB1
vary in different tumor types and evolve along with tumor pro-
gression, implying that somemalignant cellsmay expressHMGB1
to levels that are not compatible with the activation of TLR4 and
RAGE in immune cells upon release (134, 135). Importantly, the
immunogenicity of anthracycline-induced RCD is compromised
in these cells, as well in cells artificially depleted of HMGB1 by
means of specific siRNAs (135). Recent results indicate that this
defect can be efficiently corrected by the exogenous supply of a
synthetic TLR4 agonist, i.e., dendrophilin, at least in experimental
models (135). Since dendrophilin has not yet entered clinical
development (130, 131), it will be interesting to see whether
TLR4 agonists that are already licensed by regulatory agencies
for use in humans, such as the Bacillus Calmette–Guérin (BCG)
(80) and monophosphoryl lipid A (MPL) (136), are also able to
restore the immunogenicity of HMGB1-deficient cells succumb-
ing to ICD.
In this context, it is worth noting that cancer cells exposing
CALR, secreting ATP, producing type I IFNs but releasing limited
amounts of HMGB1 as they respond to a lethal stimulus in a
suboptimalmanner fail to elicit adaptive immune responses (137).
Upon inoculation into immunocompetent mice, these cells actu-
ally form tumors at the vaccination site (as a significant fraction
of them is not dying) and the animals are unable to control a
subsequent challenge with cell of the same type (3). We have
observed this to occur in murine cancer cells treated with digoxin
or digitoxin, two glycosides approved in many countries for the
treatment of cardiac conditions (81). These molecules efficiently
inhibit the human Na+/K+ ATPase, which explains their phar-
macological properties and their ability to kill some neoplastic
cells of human origin, but not its murine counterpart (83). Thus,
cardiac glycosides per se are unable to trigger ICD, at least in
the murine system. However, clinical data indicate that they may
convert non-immunogenic RCD as elicited by a very large panel of
chemotherapeutics into bona fide ICD (83). From another stand-
point, any anticancer agent that efficiently kills malignant cells
could be considered as a means to restore the immunogenicity of
cells responding to cardiac glycosides.We have recently initiated a
clinical trial to prospectively test this hypothesis in head and neck
squamous carcinoma patients.
Concluding Remarks
In spite of old beliefs, cancer cells continuously interact with the
immune system: first, as they are generated by healthy cells upon
malignant transformation; second, as they evolve and acquire
additional neoplastic features; and third, when they are challenged
with therapeutic interventions. During the last decade, such a con-
ceptual revolution, i.e., considering tumors as entities that can be
detected and destroyed by the immune system, has paved the way
toward the development of novel therapeutic agents conceived to
re(instate) anticancer immunity, and some of these interventions
have already been licensed for use in humans by international
regulatory agencies. In addition, it has become clear that many
therapeutics that had been used for decades in the clinic are effi-
cient (for themost part) because they engage the host immune sys-
tem against malignant cells. ICD is one of the several mechanisms
through which cytotoxic chemotherapeutics, targeted anticancer
agents as well as some forms of radiotherapy can elicit tumor-
targeting immune responses. Identifying novel ICD inducers as
well as measures that convert non-immunogenic RCD into bona
fide ICD is of primordial importance. Promising preclinical results
and preliminary clinical findings suggest, indeed, that agents that
promote CALR exposure, ATP secretion, type I IFN production,
HMGB1 release or stimulate the downstream signal transduction
pathway may considerably improve the clinical profile of conven-
tional therapeutic regimens (Figure 1). A systematic investigation
of the ability of currently available anticancer agents to elicit
the abovementioned ICD-associated processes in human cancer
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FIGURE 1 | Strategies to convert non-immunogenic RCD into bona fide
ICD. Upon inoculation into immunocompetent syngeneic hosts, cancer cells
responding to a panel of lethal stimuli trigger an adaptive immune response
against dead cell-associated antigens. Such an immunogenic variant of
regulated cell death (RCD), commonly known as immunogenic cell death (ICD),
relies on the exposure of calreticulin (CALR) on the cell surface, on the secretion
of ATP, on the production of type I interferons (IFNs) and on the release of
high-mobility group box 1 (HMGB1, which accompanies cell death). When any
of these damage-associated molecular patterns cannot be emitted (in the
appropriate spatiotemporal order), dying cancer cells cannot be perceived
anymore as immunogenic by the host immune system. Several strategies have
been conceived to correct these defects, hence converting non-immunogenic
RCD into bona fide ICD. ER, endoplasmic reticulum; IFNAR, interferon (alpha,
beta, and omega) receptor; P2RX7, purinergic receptor P2X, ligand gated ion
channel, 7; P2RY2, purinergic receptor P2Y, G-protein coupled, 2; TLR, toll-like
receptor.
cells of distinct histological origin is urgently awaited. These data
may pave the way to the clinical implementation of combinato-
rial immuno(chemo)regimens that efficiently promote ICD and
hence mediate complete tumor regression in a high proportion of
patients.
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